The following articles (labelled with PubMed ID or TBD) are for your review
||Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.
||Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists.
||Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
||Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.
||The University of Mississippi
||Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
||Universit£ di Siena
||2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
||Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships.
||Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system.
||Specific nonpeptide photoprobes as tools for the structural study of the angiotensin II AT(1) receptor.
||Laboratoires Fournier S.A.
||Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.
||Taisho Pharmaceutical Co., Ltd
||N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
||Pudue Pharma Discovery Research
||Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors.
||ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.
||Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist.
||Parke-Davis Pharmaceutical Research
||RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist.
||Syntex Discovery Research